PT  - JOURNAL ARTICLE
AU  - TETSUHIRO IIDA
AU  - HIROAKI NOZAWA
AU  - HIROFUMI SONODA
AU  - KAZUHIRO TOYAMA
AU  - KAZUSHIGE KAWAI
AU  - KEISUKE HATA
AU  - TOSHIAKI TANAKA
AU  - TAKESHI NISHIKAWA
AU  - KAZUHITO SASAKI
AU  - YASUTAKA SHUNO
AU  - MANABU KANEKO
AU  - KOJI MURONO
AU  - SHIGENOBU EMOTO
AU  - HIROAKI ISHII
AU  - MINEO KUROKAWA
AU  - SOICHIRO ISHIHARA
TI  - Upfront Surgery for Small Intestinal Non-Hodgkin's Lymphoma
AID  - 10.21873/anticanres.14206
DP  - 2020 Apr 01
TA  - Anticancer Research
PG  - 2373--2377
VI  - 40
IP  - 4
4099  - http://ar.iiarjournals.org/content/40/4/2373.short
4100  - http://ar.iiarjournals.org/content/40/4/2373.full
SO  - Anticancer Res2020 Apr 01; 40
AB  - Background/Aim: The clinical significance of surgery for secondary small intestinal non-Hodgkin's lymphomas (NHL) remains unknown. This study aimed to investigate the efficacy of resection for both primary and secondary small intestinal NHL. Patients and Methods: Twenty patients with small intestinal lymphoma who underwent surgical resection at our Institute between 2009 and 2017 were retrospectively evaluated. The clinicopathological and surgery-related factors were reviewed. We also analyzed their surgical outcomes such as postoperative complications, perforation rate, and overall survival (OS). Results: In total, 13 (65%) and 7 (35%) patients had primary and secondary lymphomas, respectively. A total of 70% of patients were diagnosed with aggressive-type lymphomas. A total of 15 (75%) patients had Lugano system stage IV. Only one (5%) patient experienced postoperative grade II deep vein thrombosis and pulmonary embolism. The 3-year OS rate after surgery was 59.6%. Conclusion: Surgical resection prior to chemotherapy is a feasible and safe therapeutic strategy for small intestinal NHL.